Table 1.
Baseline characteristics of PBC patients.
| All patients (n = 266) | Group A (n = 196) | Group B (n = 41) | Group C (n = 29) | P value | |
|---|---|---|---|---|---|
| Demographic characteristics | |||||
| Age | 58.35 ± 11.02 | 58.95 ± 11.19 | 58.78 ± 10.72 | 53.83 + 9.46 | .058 |
| Sex | |||||
| Female | 233 (87.6%) | 170 (86.7%) | 37 (90.2%) | 26 (89.6%) | .758 |
| Male | 33 (12.4%) | 26 (13.3%) | 4 (9.8%) | 3 (10.4%) | |
| Immune parameters | |||||
| IgA (g/L) | 3.14 (0.35–20.30) | 3.10 (0.35–20.3) | 3.46 (0.82–16.70) | 3.36 (1.03–9.66) | .986 |
| IgG (g/L) | 16.50 (1.87–61.10) | 16.40 (1.87–61.1) | 15.55 (2.12–26.10) | 18.90 (2.92–46.10) | .232 |
| IgM (g/L) | 2.90 (0.456–30.30) | 2.92 (0.45–30.30) | 2.99 (0.83–10.50) | 2.82 (0.65–6.96) | .879 |
| AMA-M2 | 601.82 (34.13–1033.36) | 520.32 (34.13–1033.36) | 644.39 (45.61–934.07) | 658.89 (514.19–803.59) | .705 |
| Biochemistry profiles | |||||
| ALT (U/L) | 38 (8–2010) | 40.5 (8–2010) | 45 (16–590) | 28 (13–784) | .883 |
| AST (U/L) | 43 (15–1370) | 43 (16–1370) | 51 (19–198) | 36.5 (15–544) | .691 |
| GGT (U/L) | 129 (8–1889) | 130.5 (8–1889) | 129 (16–1000) | 106 (25–472) | .736 |
| ALP (U/L) | 142 (43–1496) | 139.5 (43–1496) | 185 (58–908) | 147 (48–615) | .216 |
| ALB (g/L) | 42.30 (24.90–53.30) | 42.55 (24.90–53.30) | 41.90 (25.60–48.50) | 42.20 (30.70–50.40) | .731 |
| TBIL (μmol/L) | 15.00 (4.70–150.10) | 14.90 (6.00–138.70) | 14.80 (7.90–150.10) | 18.00 (4.70–49.80) | .080 |
| PLT (109/L) | 183 (6–502) | 183 (14–502) | 181 (11–327) | 183 (6–370) | .646 |
| Liver cirrhosis | 35 (13.16%) | 23 (11.73%) | 4 (9.76%) | 8 (27.59%) | .140 |
P-value represents a comparison between three groups.
Age is expressed as mean ± SD. Other characteristics are shown as the median (minimum and maximum). Statistical analysis was performed using one-way ANOVA.
ALB = albumin, ALP = alkaline phosphatase, ALT = alanine amino-transferase, AMA-M2 = anti-mitochondrial antibody-M2, AST = aspartate aminotransferase, GGT = γ-glutamyl transpeptidase, Group A = UDCA monotherapy group, Group B = dual-combination therapy group, Group C = triple-combination therapy group, IgA = immunoglobulin A, IgG = immunoglobulin G, IgM = immunoglobulin M, PBC = primary biliary cholangitis, PLT = platelets, TBIL = total bilirubin.